TY - JOUR
T1 - A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors
AU - Beatty, Gregory L.
AU - Shahda, Safi
AU - Beck, Thaddeus
AU - Uppal, Nikhil
AU - Cohen, Steven J.
AU - Donehower, Ross
AU - Gabayan, Afshin Eli
AU - Assad, Albert
AU - Switzky, Julie
AU - Zhen, Huiling
AU - Von Hoff, Daniel D.
N1 - Funding Information:
The authors thank the patients and their families, investigators, and site personnel who participated in this study. Medical writing assistance was provided by Felicity Leigh, Ph.D., of Evidence Scientific Solutions (Philadelphia, PA) and funded by Incyte Corporation. Additional funding to support G.L.B. was provided by grant 2013107 from the Doris Duke Charitable Foundation.
Publisher Copyright:
© AlphaMed Press; the data published online to support this summary is the property of the authors
PY - 2019/1
Y1 - 2019/1
N2 - Lessons Learned: Itacitinib in combination with nab-paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity in patients with advanced solid tumors including pancreatic cancer. The results support future studies of itacitinib as a component of combination regimens with other immunologic and targeted small molecule anticancer agents. Background: Cytokine-mediated signaling via JAK/STAT is central to tumor growth, survival, and systemic inflammation, which is associated with cancer cachexia, particularly in pancreatic cancer. Because of their centrality in the pathogenesis of cancer cachexia and progression, JAK isozymes have emerged as promising therapeutic targets. Preclinical studies have demonstrated antiproliferative effects of JAK/STAT pathway inhibition in both in vitro and in vivo models of cancer, including pancreatic cancer. Methods: This phase Ib/II dose-optimization study assessed itacitinib, a selective JAK1 inhibitor, combined with nab-paclitaxel plus gemcitabine in adults with treatment-naïve advanced/metastatic disease (Part 1) or pancreatic adenocarcinoma (Parts 2/2A; NCT01858883). Starting doses (Part 1) were itacitinib 400 mg, nab-paclitaxel 125 mg/m 2 , and gemcitabine 1,000 mg/m 2 . Additional dose levels incorporated were granulocyte colony-stimulating factor, de-escalations of itacitinib to 300 mg once daily (QD), nab-paclitaxel to 100 mg/m 2 , and gemcitabine to 750 mg/m 2 . Results: Among 55 patients in Part 1, 6 developed seven hematologic dose-limiting toxicities (Cycle 1). Itacitinib 300 mg plus nab-paclitaxel 125 mg/m 2 and gemcitabine 1,000 mg/m 2 was tolerated and expanded in Part 2. Treatment discontinuation and grade 3/4 neutropenia rates prompted itacitinib de-escalation to 200 mg QD in Part 2A. The most common grade 3/4 toxicities were fatigue and neutropenia. Partial responses occurred across all itacitinib doses and several tumor types (overall response rate, 24%). Conclusion: Itacitinib plus chemotherapy demonstrated acceptable safety and clinical activity in patients with advanced solid tumors including pancreatic cancers. This study was terminated early (sponsor's decision) based on negative phase III results for a JAK1/2 inhibitor in previously treated advanced pancreatic cancer.
AB - Lessons Learned: Itacitinib in combination with nab-paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity in patients with advanced solid tumors including pancreatic cancer. The results support future studies of itacitinib as a component of combination regimens with other immunologic and targeted small molecule anticancer agents. Background: Cytokine-mediated signaling via JAK/STAT is central to tumor growth, survival, and systemic inflammation, which is associated with cancer cachexia, particularly in pancreatic cancer. Because of their centrality in the pathogenesis of cancer cachexia and progression, JAK isozymes have emerged as promising therapeutic targets. Preclinical studies have demonstrated antiproliferative effects of JAK/STAT pathway inhibition in both in vitro and in vivo models of cancer, including pancreatic cancer. Methods: This phase Ib/II dose-optimization study assessed itacitinib, a selective JAK1 inhibitor, combined with nab-paclitaxel plus gemcitabine in adults with treatment-naïve advanced/metastatic disease (Part 1) or pancreatic adenocarcinoma (Parts 2/2A; NCT01858883). Starting doses (Part 1) were itacitinib 400 mg, nab-paclitaxel 125 mg/m 2 , and gemcitabine 1,000 mg/m 2 . Additional dose levels incorporated were granulocyte colony-stimulating factor, de-escalations of itacitinib to 300 mg once daily (QD), nab-paclitaxel to 100 mg/m 2 , and gemcitabine to 750 mg/m 2 . Results: Among 55 patients in Part 1, 6 developed seven hematologic dose-limiting toxicities (Cycle 1). Itacitinib 300 mg plus nab-paclitaxel 125 mg/m 2 and gemcitabine 1,000 mg/m 2 was tolerated and expanded in Part 2. Treatment discontinuation and grade 3/4 neutropenia rates prompted itacitinib de-escalation to 200 mg QD in Part 2A. The most common grade 3/4 toxicities were fatigue and neutropenia. Partial responses occurred across all itacitinib doses and several tumor types (overall response rate, 24%). Conclusion: Itacitinib plus chemotherapy demonstrated acceptable safety and clinical activity in patients with advanced solid tumors including pancreatic cancers. This study was terminated early (sponsor's decision) based on negative phase III results for a JAK1/2 inhibitor in previously treated advanced pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=85054823318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054823318&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2017-0665
DO - 10.1634/theoncologist.2017-0665
M3 - Article
C2 - 30115734
AN - SCOPUS:85054823318
SN - 1083-7159
VL - 24
SP - 14-e10
JO - Oncologist
JF - Oncologist
IS - 1
ER -